Phase 2 Clinical Trial For Kidney Injury Started By AlloCure

AlloCure, Inc. introduced that it has started a phase 2 clinical trial of AC607, the organization's mesenchymal stem cell therapy, as a possible therapy for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center trial, allotted ACT-AKI (AC607 Trial in Acute Kidney Injury) (NCT01602328), will register 200 cardiac surgery topics at leading tertiary care centers in the United States.

"ACT-AKI follows the constructive achievements from a phase 1 AC607 trial in cardiac surgery subjects, which generally showed a good safety traits and inspiring data on the likelihood of AKI and hospital duration of stay," said Robert M. Brenner, M.D., AlloCure President and Chief Executive Officer. "We have now worked closely along with leaders in the field upon the design of ACT-AKI, and trial initiation symbolizes a necessary milestone for AlloCure and of course the affected individuals we collectively serve."

"AC607 is a promising therapeutic applicant for AKI, for which most effective therapies are tremendously needed," said Richard J. Glassock, M.D., Emeritus Professor of Medicine at the Geffen School of Medicine at the University of California, Los Angeles. "The initiation of ACT-AKI represents an important step in the creation of an innovative session for that all-too-common, serious and costly medical problem, for which generally no approved therapies currently live beyond supportive care."